Nu.Q® Biomarkers Clinical Study Published in Shock Journal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy VNRX?
Source: Newsfilter
- Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
- Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
- Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
- Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.202
Low
1.50
Averages
2.25
High
3.00
Current: 0.202
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
VolitionRx Secures €2 Million Non-Dilutive Financing
- Funding for Development: VolitionRx secured €2 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre, which will be used to support the development of its Nu.Q product portfolio, particularly the regulatory transition work for Nu.Q NETs, potentially accelerating the product's market entry.
- Strategic Financing Plan: This financing is part of the company's strategy to secure non-dilutive funding for ongoing development, with total non-dilutive funding to date exceeding $25 million, enhancing the company's financial stability and R&D capabilities.
- Improving Access in Low-Income Countries: The funds will be directed towards the development of a lateral flow product aimed at improving access to medical products in low-income countries, reflecting the company's commitment to global health equity while laying the groundwork for future market expansion.
- Stock Price Reaction: Following the financing announcement, VolitionRx's stock price rose by 0.05% in pre-market trading to $0.1901, indicating a positive market sentiment regarding the company's financing and growth prospects.
See More
Nu.Q® Biomarkers Clinical Study Published in Shock Journal
- Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
- Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
- Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
- Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.
See More
VolitionRx to Host Earnings Call on April 1, 2026
- Earnings Call Announcement: VolitionRx will host a conference call on April 1, 2026, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for fiscal year 2025, aiming to provide investors with the latest business updates.
- Key Participants: The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, with participation from President and CEO Cameron Reynolds, CFO Terig Hughes, and other executives, ensuring a comprehensive interpretation of significant company events and future milestones.
- Replay Information: A telephone replay of the call will be available until April 15, 2026, with a toll-free dial-in number of 1-844-512-2921 for the U.S. and Canada, and an international number of 1-412-317-6671, ensuring that investors who cannot attend live can access key information.
- Company Overview: VolitionRx focuses on advancing the science of epigenetics, dedicated to improving the quality of life for humans and animals through early detection and monitoring of diseases, developing simple and cost-effective blood tests to detect cancers and diseases associated with NETosis, highlighting its strategic importance in the healthcare sector.
See More
VolitionRx's Breakthrough Liquid Biopsy Technology Achieves High Detection Rates
- Technological Breakthrough: VolitionRx's Capture-Seq liquid biopsy technology successfully detected over 95% of stage I and II cancers in a blinded validation, showcasing its immense potential in multi-cancer early detection and addressing the urgent market need for early diagnosis.
- Significant Detection Rates: Among 81 participants, Capture-Seq achieved a 94% detection rate for stage I cancers and 96% for stage II, with an overall sensitivity of 93% and a specificity of 95% among healthy controls, laying a solid foundation for future clinical applications.
- Broad Market Potential: VolitionRx estimates a total addressable market of approximately $23 billion for human multi-cancer early detection and over $13 billion for minimal residual disease applications, highlighting the commercial viability and attractiveness of this technology.
- Increased Collaboration Opportunities: The company is in discussions with several major liquid biopsy and diagnostic firms to accelerate development and commercialization, with Capture-Seq's strong results generating significant interest from potential licensing partners.
See More
VolitionRx Achieves Breakthrough with New Liquid Biopsy Method
- New Cancer Detection Method: VolitionRx announced that its new liquid biopsy method achieved over 95% sensitivity and specificity for stage I and II cancers during a blinded validation cohort, marking a significant advancement in early cancer detection that could enhance its market competitiveness.
- Stock Price Surge: Following this announcement, VolitionRx shares surged more than 34% in pre-market trading on Wednesday, reflecting strong investor confidence in the company's new technology and a positive market reaction that may attract further investor interest.
- Optimistic Market Sentiment: According to data from Stocktwits, retail sentiment around VolitionRx trended bullish, with message volumes at extremely high levels, indicating strong market recognition of its new technology and active investor participation, potentially driving further stock price increases.
- Future Growth Potential: As liquid biopsy technology continues to mature, VolitionRx is poised to capture a larger share of the cancer detection market, particularly in early diagnosis, which will provide the company with long-term growth opportunities and strategic advantages.
See More
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
VolitionRx Secures €2 Million Non-Dilutive Financing
- Funding for Development: VolitionRx secured €2 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre, which will be used to support the development of its Nu.Q product portfolio, particularly the regulatory transition work for Nu.Q NETs, potentially accelerating the product's market entry.
- Strategic Financing Plan: This financing is part of the company's strategy to secure non-dilutive funding for ongoing development, with total non-dilutive funding to date exceeding $25 million, enhancing the company's financial stability and R&D capabilities.
- Improving Access in Low-Income Countries: The funds will be directed towards the development of a lateral flow product aimed at improving access to medical products in low-income countries, reflecting the company's commitment to global health equity while laying the groundwork for future market expansion.
- Stock Price Reaction: Following the financing announcement, VolitionRx's stock price rose by 0.05% in pre-market trading to $0.1901, indicating a positive market sentiment regarding the company's financing and growth prospects.
See More
Nu.Q® Biomarkers Clinical Study Published in Shock Journal
- Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
- Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
- Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
- Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.
See More
VolitionRx to Host Earnings Call on April 1, 2026
- Earnings Call Announcement: VolitionRx will host a conference call on April 1, 2026, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for fiscal year 2025, aiming to provide investors with the latest business updates.
- Key Participants: The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, with participation from President and CEO Cameron Reynolds, CFO Terig Hughes, and other executives, ensuring a comprehensive interpretation of significant company events and future milestones.
- Replay Information: A telephone replay of the call will be available until April 15, 2026, with a toll-free dial-in number of 1-844-512-2921 for the U.S. and Canada, and an international number of 1-412-317-6671, ensuring that investors who cannot attend live can access key information.
- Company Overview: VolitionRx focuses on advancing the science of epigenetics, dedicated to improving the quality of life for humans and animals through early detection and monitoring of diseases, developing simple and cost-effective blood tests to detect cancers and diseases associated with NETosis, highlighting its strategic importance in the healthcare sector.
See More
VolitionRx's Breakthrough Liquid Biopsy Technology Achieves High Detection Rates
- Technological Breakthrough: VolitionRx's Capture-Seq liquid biopsy technology successfully detected over 95% of stage I and II cancers in a blinded validation, showcasing its immense potential in multi-cancer early detection and addressing the urgent market need for early diagnosis.
- Significant Detection Rates: Among 81 participants, Capture-Seq achieved a 94% detection rate for stage I cancers and 96% for stage II, with an overall sensitivity of 93% and a specificity of 95% among healthy controls, laying a solid foundation for future clinical applications.
- Broad Market Potential: VolitionRx estimates a total addressable market of approximately $23 billion for human multi-cancer early detection and over $13 billion for minimal residual disease applications, highlighting the commercial viability and attractiveness of this technology.
- Increased Collaboration Opportunities: The company is in discussions with several major liquid biopsy and diagnostic firms to accelerate development and commercialization, with Capture-Seq's strong results generating significant interest from potential licensing partners.
See More
VolitionRx Achieves Breakthrough with New Liquid Biopsy Method
- New Cancer Detection Method: VolitionRx announced that its new liquid biopsy method achieved over 95% sensitivity and specificity for stage I and II cancers during a blinded validation cohort, marking a significant advancement in early cancer detection that could enhance its market competitiveness.
- Stock Price Surge: Following this announcement, VolitionRx shares surged more than 34% in pre-market trading on Wednesday, reflecting strong investor confidence in the company's new technology and a positive market reaction that may attract further investor interest.
- Optimistic Market Sentiment: According to data from Stocktwits, retail sentiment around VolitionRx trended bullish, with message volumes at extremely high levels, indicating strong market recognition of its new technology and active investor participation, potentially driving further stock price increases.
- Future Growth Potential: As liquid biopsy technology continues to mature, VolitionRx is poised to capture a larger share of the cancer detection market, particularly in early diagnosis, which will provide the company with long-term growth opportunities and strategic advantages.
See More
